OncoSec Medical Inc (ONCSQ)

[DrBob99]

I mentioned that "it looks like he is losing interest". My reasoning is that he doesn't include EP IL12 on slide 34 of the deck and take a look at the following site. http://www.merkelcell.org/news/

1/14 there is a picture of him holding a vial of the TLR-4 agonist and you have to scroll down to 1/12 to see a detailed description of EP IL-12.

For such a rare disease it's tough to be involved with what appears to be 3 separate projects (clinicaltrials.gov only lists two MCC trials, but this site list three separate agents). There just aren't enough patients.

The bottom line is that this Dr. Bhatia is an internationally recognized MCC expert and Oncosec needs to do their part to keep him engaged and enrolling patients.

The answer to your second question is yes, Toll like receptor agonist 4 agents do function as immunomodulators. They are among a newer class of agents